Number of Shares and Voting Rights of ADOCIA as of February 28th, 2021
March 17 2021 - 1:00PM
Business Wire
Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French
« Code de Commerce » and article 223-16 of the French stock-market
authorities (Autorité des Marchés Financiers, or “AMF”) charter
ADOCIA SA (Paris:ADOC), a French société anonyme (corporation),
115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 –
ADOC) a clinical stage biopharmaceutical company focused on
diabetes treatment with innovative formulations of approved
proteins, releases its total number of outstanding shares as well
as its voting rights as of February 28th, 2021.
Month
Date
Total number of outstanding
shares
Total number of theoretical
voting rights (1)
Total number of exercisable
voting rights (2)
February
02/28/2021
7 020 854
9 789 012
9 773 093
(1) The total number of theoretical voting rights (or “gross”
voting rights) is used as the basis for calculating the crossing of
shareholding thresholds. In accordance with Article 223-11 of the
AMF General Regulation, this number is calculated on the basis of
all shares to which voting rights are attached, including shares
whose voting rights have been suspended.
(2) The total number of exercisable voting rights (or” net”
voting rights) is calculated without taking into account the shares
with suspended voting rights, in this case, shares held by the
Company in the context of a liquidity agreement.
About Adocia
Adocia is a clinical-stage biotechnology company that
specializes in the development of innovative formulations of
therapeutic proteins and peptides for the treatment of diabetes and
metabolic diseases. In the diabetes field, Adocia’s portfolio of
injectable treatments is among the largest and most differentiated
of the industry, featuring four clinical-stage products. The
proprietary BioChaperone® technological platform is designed to
enhance the effectiveness and/or safety of therapeutic proteins
while making them easier for patients to use. Adocia customizes
BioChaperone to each protein for a given application.
Adocia’s clinical pipeline includes four novel insulin
formulations for prandial treatment of diabetes: two ultra-rapid
formulations of insulin analog lispro (BioChaperone® Lispro U100
and U200), a combination of basal insulin glargine and rapid acting
insulin lispro (BioChaperone® Combo) and one combination of a
prandial insulin with amylin analog pramlintide M1Pram. The
clinical pipeline also includes an aqueous formulation of human
glucagon (BioChaperone® Glucagon) for the treatment of
hypoglycemia.
Adocia preclinical pipeline includes four products: combinations
of rapid human insulin analogus and Pramlintide (BioChaperone®
LisPram and BioChaperone® AsPram), a combination of insulin
glargine with GLP-1 receptor agonists (BioChaperone® Glargine
GLP-1) for the treatment of diabetes and a ready-to-use combination
of glucagon and a GLP-1 receptor agonist (BioChaperone® Glucagon
GLP-1) for the treatment of obesity.
Adocia recently added a fifth program, a preclinical stage cell
therapy initiative focused on development of a hydrogel scaffold
for use in people with type 1 diabetes. The first patent
application supporting this program has been filed.
Disclaimer
This press release contains certain forward-looking statements
concerning Adocia and its business. Such forward-looking statements
are based on assumptions that Adocia considers to be reasonable.
However, there can be no assurance that the estimates contained in
such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the
“Risk Factors” section of the Universal Registration Document filed
with the French Autorité des marchés financiers on April 22, 2020
(a copy of which is available at www.adocia.com) and to the
development of economic conditions financial markets and the
markets in which Adocia operates. The forward-looking statements
contained in this press release are also subject to risks not yet
known to Adocia or not currently considered material by Adocia. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance, or achievements of Adocia to be
materially different from such forward-looking statements. This
press release and the information contained herein do not
constitute an offer to sell or the solicitation of an offer to buy
Adocia shares in any jurisdiction.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210317005645/en/
Adocia Gérard Soula CEO contactinvestisseurs@adocia.com Ph: +33
4 72 610 610 www.adocia.com
MC Services AG Adocia Press Relations Europe Raimund Gabriel
Managing Partner adocia@mc-services.eu Ph: +49 89 210 228 0
The Ruth Group Adocia Investor Relations USA James Salierno
Vice-President jsalierno@theruthgroup.com Ph.: +1 646 536 7035
Adocia (EU:ADOC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adocia (EU:ADOC)
Historical Stock Chart
From Apr 2023 to Apr 2024